Cancer

Affimed NV (Heidelberg, Germany)

AFM-13

Tetravalent, bispecific NK cell engager

Hodgkin lymphoma (HL) and CD30-positive lymphoma

Data from two separate studies showed that it was well-tolerated and showed promising therapeutic efficacy both in combination with the anti-PD-1 antibody Keytruda in HL and as monotherapy in CD30-positive lymphoma; the combo trial showed an objective response rate (ORR) of 89%, including complete metabolic responses in 44% and partial metabolic responses in 44% of patients with one patient experiencing stable disease (SD); the monotherapy trial demonstrated that it could be safely administered, showed therapeutic activity as a single agent with an ORR of 66% (2/3), and one CR, one PR and one SD were observed

2/2/18

Aravive Biologics Inc. (Houston)

AVB-S6-500

GAS6 inhibitor

Cancer

Started a phase I trial in 40 healthy volunteers

2/16/18

Bayer AG (Leverkusen, Germany) and Loxo Oncology Inc. (Stamford, Conn.)

Larotrectinib

Directly targets TRK

Tumors with neurotrophic tyrosine receptor kinase (NTRK) gene fusions

Data from its phase I adult trial, the phase II Navigate trial and the phase I/II pediatric Scout trial showed it demonstrated an overall response rate of 75% by central assessment and 80% by investigator assessment; at the time of analysis, 86% of responding patients remained on it or underwent surgery with curative intent; the median duration of response and progression-free survival had not been reached

2/23/18

Beigene Ltd. (Cambridge, Mass.)

Tislelizumab

Anti-PD-1 antibody

Urothelial carcinoma (UC)

Phase I data suggest that it was generally well-tolerated and exhibited objective responses; 15 patients were evaluable; one patient had a confirmed complete response (CR), four achieved a confirmed partial response (PR), and three achieved stable disease (SD); nine evaluable patients had PD-L1 status determined; there was one CR, two PRs and one SD among six PD-L1-high patients, and one PR among three PD-L1-low or negative patients

2/12/18

Briacell Therapeutics Corp. (Berkeley, Calif.)

Bria-IMT

Releases granulocyte-macrophage colony-stimulating factor

Breast cancer

Phase I/IIa data showed the regimen was well-tolerated with few side effects in the six patients who received inoculations; imaging studies on the first fully evaluable patient in the trial showed a mixed response, including "a clear response in multiple bilateral pulmonary nodules," although there was evidence of progressive disease at other sites

2/1/18

Calithera Biosciences Inc. (South San Francisco)

CB-839

Inhibitor of glutaminase

Renal cell carcinoma (RCC)

Phase I results of it in combination with Cabometyx produced a 40% overall response rate and 100% disease control in 12 evaluable patients with advanced clear cell RCC, and two additional patients with papillary RCC had disease control as well; updated results of it in combination with Afinitor showed disease control in 92% of the 24 evaluable RCC patients, including one patient with a partial response and 21 patients with stable disease, and median progression-free survival of 5.8 months

2/7/18

Cancer Research UK (London) and Bicycle Therapeutics Ltd. (Cambridge, U.K.)

BT-1718

Targets membrane type 1 matrix metalloproteinase

Advanced solid tumors

The first patient was dosed in their phase I/IIa trial

2/14/18

Cytrx Corp. (Los Angeles) and Nantcell Inc. (Culver City, Calif., subsidiary of Nantworks LLC)

Aldoxorubicin

Cytotoxic delivering doxorubicin

Advanced squamous cell carcinoma of either head and neck or non-small-cell lung cancer

Dosed the first patient in the phase Ib portion of a phase Ib/II trial

2/6/18

Daiichi Sankyo Co. Ltd. (Tokyo)

U3-1402

HER3-targeting antibody-drug conjugate

Metastatic or unresectable EGFR-mutated non-small-cell lung cancer

The first patient was dosed in a phase I study

2/7/18

Daiichi Sankyo Co. Ltd. (Tokyo)

DS-1062

Trophoblast cell-surface antigen 2 (TROP2)-targeting antibody-drug conjugate

Unresectable advanced non-small-cell lung cancer

The first patient was dosed in a phase I study

2/23/18

Exelixis Inc. (South San Francisco)

Cabometyx

Cabozantinib

Refractory genitourinary tumors

Expansion cohorts in a phase I trial of it in combination with either Opdivo or Opdivo plus Yervoy showed: 19 patients with metastatic urothelial carcinoma (mUC) were evaluable for response with a median follow-up of 15.7 months, with an overall response rate (ORR) of 42% (two complete responses [CRs] and six partial responses [PRs]) and disease control rate of 84%; seven of eight (88%) mUC patients with an objective response had not progressed at the time of the data cut-off; median progression-free survival in that patient population was 12.8 months, and the overall survival rate at 12 months was 77%; in the overall study, the ORR in 64 evaluable patients was 36% (three CRs and 20 PRs), with a median duration of response of 24 months

2/8/18

Fate Therapeutics Inc. (San Diego)

FATE-NK100

Allogeneic natural killer cell cancer immunotherapy

Advanced solid tumors

Treated the first patient in the phase I DIMENSION trial

2/21/18

Gamida Cell Ltd. (Jerusalem)

Nicord

Universal bone marrow transplant solution

High-risk hematologic malignancies

A phase I/II trial met its primary endpoint; participants experienced rapid and durable neutrophil engraftment at a median of 11 days, representing an improvement over historical standard cord blood transplantation as well as compared to a database of patients from the Center for International Blood and Marrow Transplant Research; it demonstrated an acceptable safety profile, with moderate/severe chronic graft-vs.-host disease in 9.8% of patients at one year following transplantation

2/21/18

Immunicum AB (Gothenburg, Sweden)

Ilixadencel

Dendritic cell therapy

Hepatocellular carcinoma

A phase I/II case study of a patient with bile duct cancer who was treated with it intratumorally after transarterial chemo-embolization treatment with doxorubicin showed delayed progression of the tumor until month six; the patient then received gemcitabine plus cisplatin and lived for 41 months, substantially longer than historical controls

2/6/18

Immutep Ltd. (Sydney)

LAG-3Ig or IMP-321

Eftilagimod alpha

Unresectable or metastatic melanoma

In the TACTI-mel (Two ACTive Immunotherapies in melanoma) phase I trial, the database safety monitoring board confirmed it is safe and well-tolerated in combination with Keytruda at doses up to 30 mg per subcutaneous injection

2/12/18

Intensity Therapeutics Inc. (Westport, Conn.)

INT-230-6

Amphiphilic cell penetration enhancer molecule with cisplatin and vinblastine

Ovarian, thyroid, head and neck or skin cancers

Data from cohort A of its phase I/II trial showed there were no dose-limiting toxicities; treatment was started in cohort B1

2/28/18

Kancera AB (Stockholm, Sweden)

KAND-567

Targets CX3CR1

Lymphoma and cardiovascular disease

Data from a phase I trial testing it in healthy volunteers showed it was safe and well-tolerated at up to 500 mg twice daily for seven days, with plasma levels five to 10 times higher than the calculated effective level for a therapeutic effect in humans

2/21/18

Mabvax Therapeutics Holdings Inc. (San Diego)

MVT-5873

Monoclonal antibody that targets an epitope on CA19-9 called sialyl Lewis A

Pancreatic cancer

Interim phase I data from the expanded cohort testing it in combination with first-line chemotherapy showed all six patients had measurable tumor reductions, including four partial responses and two patients with stable disease

2/13/18

MEI Pharma Inc. (San Diego)

ME-344

Novel mitochondrial inhibitor

HER2-negative breast cancer

Interim data from the first 20 patients in a study testing it in combination with Avastin justifies completing enrollment of the expected 40 total patients

2/14/18

Nantkwest Inc. (Culver City, Calif.)

HER2.taNK

Natural killer cell-based immuno-oncology therapy

HER2-positive glioblastoma

Treated the first patient in a phase I trial

2/14/18

Oasmia Pharmaceutical AB (Uppsala, Sweden)

Docecal

Nanoparticle formulation of docetaxel

Metastatic breast cancer

Completed treatment of 228 patients in a pharmacokinetic crossover clinical phase I study and a randomized clinical study comparing it to Taxotere

2/21/18

Oncoceutics Inc. (Philadelphia)

ONC-201

Small-molecule DRD2 antagonist

Brain tumors containing the histone H3 K27M mutation

The first patient was treated in a trial of pediatric patients

2/1/18

Oncopep Inc. (Boston)

PVX-410

Multipeptide therapeutic cancer vaccine

Metastatic triple-negative breast cancer, human leukocyte antigen A2-positive

Started a phase Ib trial

2/23/18

Orano Med  (Courbevoie, France) and Radiomedix Inc. (Houston)

Alphamedix

Radiolabeled SSTR-targeting therapeutic

Somatostatin receptor-positive neuroendocrine tumors

Dosed the first three patients in the phase I trial

2/21/18

Panacea Pharmaceuticals Inc. (Gaithersburg, Md.)

PAN-301-1

Nanoparticle immunotherapy vaccine

Persistent prostate cancer

Completed enrollment of 12 patients in a phase I trial; it has been well-tolerated with a highly favorable safety profile across all dose levels with no drug-related adverse events or dose-limiting toxicities observed; all subjects experienced dose-dependent HAAH-specific immune responses, including antibody levels in immunoassays and B-cell and T-cell responses, and a majority of subjects treated beyond three months achieved a reduction in prostate-specific antigen doubling rate and are receiving continued doses

2/2/18

Redx Pharma Ltd. (Alderley Park, U.K.)

RXC-004

Porcupine inhibitor

Cancer

Started a phase I/IIa study

2/7/18

Scancell Holdings plc (Nottingham, U.K.)

SCIB1

Cancer vaccine

Melanoma

Phase I/II data showed that of the 20 stage III/IV patients, 18 were alive as of the February 2018 cutoff; six of the 16 resected patients who received 2-4 mg doses had recurrence of their disease with two deaths; of the 14 surviving patients, all have lived for at least five years

2/13/18

Sosei Group Corp. (Tokyo) and Astrazeneca plc (Cambridge U.K.)

AZD-4635

Selective adenosine A2A receptor antagonist

Advanced solid tumors

Dosed the first patient in the phase Ib portion of a trial testing alone and in combination with durvalumab

2/9/18

Targovax ASA (Oslo, Norway)

ONCOS-102

Virus-based oncolytic immunotherapy

Mesothelioma

Completed the safety lead-in cohort and preliminary immune activation data in the phase I/II trial

2/8/18

TG Therapeutics Inc. (New York)

TGR-1202

Umbralisib

Relapsed or refractory B-cell malignancies

Phase I data showed that in patients with relapsed or refractory chronic lymphocytic leukemia, it produced an 85% objective response rate (ORR), including 50% per International Workshop on Chronic Lymphocytic Leukemia criteria and 35% partial response with lymphocytosis; in patients with relapsed or refractory follicular lymphoma, it produced a 53% ORR

2/22/18

Trovagene Inc. (San Diego)

PCM-075

Oral PLK1-selective adenosine triphosphate competitive inhibitor

Acute myeloid leukemia

The first patient completed the first cycle of dosing in combination with low-dose cytarabine in its phase Ib/II trial

2/7/18

Xencor Inc. (Monrovia, Calif.)

Xmab-18087

Bispecific antibody targeting SSTR2 and CD3

Neuroendocrine tumors and gastrointestinal stromal tumors

Treated the first patient in a phase I trial

2/23/18

Cardiovascular

Berlin Cures Holding AG (Zug, Switzerland)

BC-007

DNA aptamer-based compound

Dilated cardiomyopathy

Phase I data showed that a single intravenous dose is able to eliminate autoantibodies targeting the beta-1 adrenoceptor completely and sustainably; it was well-tolerated and did not provoke any clinically relevant side effects

2/28/18

Longeveron LLC (Miami

MSC

Mesenchymal stem cell therapy

Hypoplastic left heart syndrome

The first infant received treatment

2/28/18

Myokardia Inc. (South San Francisco)

MYK-491

Allosteric activator of myosin

Dilated cardiomyopathy

Dosing has begun for a phase Ib trial

2/15/18

Dermatologic

Galapagos NV (Mechelen, Belgium) and Morphosys AG (Planegg, Germany)

MOR-106

IL-17C antibody

Atopic dermatitis (AD)

In the phase I study, it showed first signs of activity and durable responses and was generally well-tolerated; at the highest dose level (10 mg/kg body weight), in 83% of patients an improvement of at least 50% in signs and extent of AD, as measured by EASI-50, was recorded at week four; onset of activity occurred within two to four weeks, depending on the dose administered

2/21/18

Mallinckrodt plc (Staines-upon-Thames, U.K.)

Expressgraft C9T1

Skin tissue

Diabetic foot ulcers

Enrolled the first patient in a phase I study

2/15/18

Sienna Biopharma-ceuticals Inc. (Westlake Village, Calif.)

SNA-125

Inhibits janus kinase 3 (JAK3) and tropomyosin receptor kinase A (TrkA)

Psoriasis and associated pruritus

The first patient was dosed in a phase I/II study

2/15/18

Endocrine/Metabolic

Abeona Therapeutics Inc. (Cleveland)

ABO-101

Adeno-associated viral-based gene therapy

Mucopoly-saccharidosis IIIB

Preliminary 30-day safety and biopotency signals from the first patient dosed in its phase I/II trial showed it was well-tolerated with no treatment-related adverse events or serious adverse events through 30 days of follow-up; significant heparan sulfate reductions were observed in cerebral spinal fluid (50%), urine (69%), plasma (60%) and urinary total glycosaminoglycan (67%); normalized NAGLU enzyme activity was observed

2/8/18

Abeona Therapeutics Inc. (Cleveland)

ABO-102

Adeno-associated viral-based gene therapy

Mucopoly-saccharidosis IIIA

The FDA allowed it to lower the enrollment age in the phase I/II trial to include subjects as young as 6 months

2/12/18

Amicus Therapeutics Inc. (Cranbury, N.J.)

ATB-200/AT-2221

Enzyme replacement therapy (ERT)

Pompe disease

Phase I/II data showed that of the eight ERT-switch patients, all eight increased their six-minute walk test at month 12 with a mean increase of 57.4 meters; both ERT-naïve patients treated for 12 months increased their six-minute walk test by a median of 86.8 meters; biomarkers of muscle damage (creatine kinase) and disease substrate (urine hexose tetrasaccharide) improved at month 12

2/9/18

Applied Therapeutics Inc. (New York)

AT-001

Oral small molecule

Diabetic complications

Initiated a phase I trial

2/13/18

Audentes Therapeutics Inc. (San Francisco)

AT-342

AAV8 vector containing a functional copy of the UGT1A1 gene

Crigler-Najjar syndrome

Initiated dosing in VALENS, a phase I/II trial

2/13/18

Biomarin Pharmaceutical Inc (San Rafael, Calif.)

BMN-250

Enzyme replacement therapy

Sanfilippo B syndrome

Interim phase I/II data showed all three treated part one patients experienced decreases in liver size into the normal range for age

2/8/18

Genethon (Evry, France)

Adeno-associated viral vector

Gene therapy

Crigler-Najjar syndrome

Started a European phase I/II trial

2/13/18

Sangamo Therapeutics Inc. (Richmond, Calif.)

SB-913

Intravenously delivered zinc finger nuclease (ZFN) therapeutic

Hunter syndrome

Safety data from the phase I/II CHAMPIONS study showed the first patient treated appeared to be tolerating the infusion well after the first six weeks, and liver function tests remained within normal limits; a second patient was treated in the study in mid-January

2/8/18

Saniona AB (Copenhagen)

Tesomet

Tesofensine and metoprolol

Type 2 diabetes

Completed recruitment in its phase I pharmacokinetic study

2/8/18

Sanofi SA (Paris)

Avalglucosidase alfa

NeoGAA

Late-onset Pompe disease

Safety data from the phase I/II NEO1 trial and the NEO-EXT extension trial showed that of the patients who completed NEO1, 19 of 24 patients entered the NEO-EXT study and 18 are still enrolled; the one discontinuation occurred for personal reasons; treatment-emergent adverse events were mostly mild across both studies

2/9/18

Valbiotis SAS, (La Rochelle, France)

VAL-070

Dietary supplement containing active plant extracts

Mild to moderate dyslipidemia

Completed recruitment for a phase I/II study

2/28/18

Gastrointestinal

Palatin Technologies Inc. (Cranbury, N.J.)

PL-8177

Selective melanocortin receptor 1 agonist peptide

Ulcerative colitis and inflammatory bowel diseases

Dosed the first healthy subject in its phase I trial

2/6/18

Genitourinary/Sexual Health

Contravir Pharmaceuticals Inc. (Edison, N.J.)

Txl

Delivers high intrahepatic concentrations of tenofovir

Severe renal impairment

Phase I showed it was safe and well-tolerated in eight healthy subjects and eight patients; the blood concentrations of tenofovir in the renally impaired patients treated with it was similar to exposure levels after treatment with Viread, suggesting dosing adjustments won't be required

2/7/18

Hematologic

Acticor Biotech SAS (Paris)

ACT-017

Humanized monoclonal antibody fragment directed against a platelet glycoprotein (GPVI)

Thrombosis

Completed a phase I trial in healthy volunteers; the primary endpoint of safety and tolerability showed no serious adverse events reported at any doses tested; the maximum tolerated dose was not reached, though the complete inhibition of collagen-induced platelet aggregation was observed, meaning that an acceptable phase II recommended dose was obtained

2/6/18

Catalyst Biosciences Inc. (South San Francisco)

CB-2679d/ISU-304

Subcutaneous (SQ) prophylactic

Hemophilia B

Phase I/II data showed a continuous linear increase in factor IX (FIX) activity levels following daily dosing for six days; it increased FIX activity levels in five patients who were each dosed daily with 140 IU/kg SQ, from very low levels after washout of prior therapy to a median FIX activity level of 16% (range 11.5% to 18%); the observed increase in FIX activity levels after the daily dosing was linear

2/12/18

Gamida Cell Ltd. (Jerusalem)

Nicord

Universal bone marrow transplant solution

Sickle cell disease

Results from a phase I/II sickle cell disease study showed rapid engraftment observed in all 13 patients at a median of seven days, with 11 of 13 patients (84.6%) alive at a median follow-up of 22 months

2/21/18

Immune

Bellicum Pharmaceuticals, Inc. (Houston)

BPX-501

Rivogenlecleucel

Graft vs. host disease after hematopoietic stem cell transplants

The FDA stopped three U.S.-based trials after three cases of encephalopathy possibly related to the experimental therapy cropped up; a European trial is unaffected

2/1/18

Bellicum Pharmaceuticals, Inc. (Houston)

BPX-501

Rivogenlecleucel

Graft vs. host disease after hematopoietic stem cell transplants

Received word from the FDA on what will be required to lift a clinical hold on U.S. studies; the company said it plans to revise U.S. study protocols, including the addition of more comprehensive monitoring and management of neurotoxicity; it will also revise the study's investigator brochure and informed consent documents to communicate the changes

2/26/18

Cynata Therapeutics Ltd. (Melbourne, Australia)

CYP-001

Cymerus mesenchymal stem cell product

Steroid-resistant graft-vs. host disease (GvHD)

Data from the first cohort of eight patients in its phase I trial showed that the overall response rate by day 100 was 100%, with all patients showing an improvement in the severity of GvHD by at least one grade compared to baseline; half of the patients had a complete response by day 100 and 87.5% were alive on day 100

2/28/18

Herantis Pharma plc (Espoo, Finland)

Lymfactin

Gene therapy expressing VEGF-C

Breast cancer-associated lymphedema

Completed enrollment in a phase I trial testing safety and tolerability

2/9/18

Therachon AG (Basel, Switzerland)

TA-46

Soluble recombinant human fibroblast growth factor receptor ligand trap

Achondroplasia

The first subject in its phase I trial was dosed

2/15/18

Infection

Arch Biopartners Inc. (Toronto)

AB-569

Ethylenediamine-tetraacetic acid and sodium nitrite

Antibiotic-resistant bacterial infections

Began to recruit and enroll healthy volunteers in a phase I trial

2/14/18

Emergent Biosolutions Inc. (Gaithersburg, Md.) and Valneva SE (Lyon, France)

VLA-1601

Vaccine

Zika virus

Started a phase I trial in healthy adults

2/28/18

Eurocine Vaccines AB (Solna, Sweden)

Immunose Flu

Quadrivalent nasal influenza vaccine

Influenza

Started a phase I/II trial in adults, ages 50 to 75

2/8/18

Hemispherx Biopharma Inc. (Banff, Alberta)

Ampligen

Rintatolimod

Influenza

A phase I/II trial testing it following treatment with Flumist in 12 healthy volunteers showed the combination produced secretory IgA antibody responses of at least fourfold over baseline against at least one of the vaccine's homologous vaccine strains in 92% of the subjects; IgA antibodies against highly pathogenic avian influenza strains H5N1, H7N9 and H7N3 were observed

2/1/18

Immuron Ltd. (Melbourne, Australia)

IMM-529

Polyclonal antibody combination

Clostridium difficile infection

Enrolled the first patients in a phase I/II trial

2/1/18

Vyera Pharmaceuticals LLC (New York)

TUR-006

Dihydrofolate reductase inhibitor

Toxoplasmosis

Started a phase I single ascending-dose study

2/12/18

Wuxi Biologics (Shanghai) and Tychan Pte Ltd. (Singapore)

Tyzivumab

Zika antibody

Zika virus

Dosed the first patient in a phase Ia trial in Singapore

2/12/18

Inflammatory

Corbus Pharmaceuticals Holdings Inc. (Norwood, Mass.)

Lenabasum

Selective cannabinoid receptor type 2 (CB2) agonist

Systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus

Study data showed treatment with 5 mg or 20 mg twice daily inhibited the accumulation of neutrophils at the infected site; it also enhanced clearance of the injected bacteria

2/16/18

Musculoskeletal

Spinalcyte LLC (Houston)

Cybrocell

Allogeneic human dermal fibroblast product

Degenerative disc disease

Phase I/II data showed approximately 70% of patients treated with it reported therapeutic improvement, including increase in regeneration, disc height, gene expression of structural genes such as collagen type I and collagen type II and the contents of structural proteins such as proteoglycan, which in turn generate the disc nucleus that provides cushioning for the spine

2/14/18

Neurology/Psychiatric

Axsome Therapeutics Inc. (New York)

AXS-09

Esbupropion and dextromethorphan

CNS disorders

Phase I data showed that it substantially increased dextromethorphan plasma concentrations, the primary endpoint, into a potentially therapeutic range with repeated dosing (p<0.0001 day one vs. day eight); it was well-tolerated with no serious adverse events reported

2/27/18

Gensight Biologics SA (Paris)

GS-010

rAAV2/2-ND4 gene therapy

Leber hereditary optic neuropathy (LHON)

Phase I/II data showed it safe and well-tolerated 96 weeks after treatment

2/21/18

Impel Neuropharma Inc. (Seattle)

INP-104

Intranasal version of dihydroergotamine dosed via Precision Olfactory Deliver device

Acute migraine

Phase I data showed a statistically significant improvement in bioavailability (Cmax and AUC) of it over a currently approved dihydroergotamine mesylate nasal spray; that bioavailability was comparable to DHE 45 (dihydroergotamine mesylate) intravenous injection after 20 minutes of exposure

2/8/18

Sage Therapeutics Inc. (Cambridge, Mass.)

SAGE-217

Positive allosteric modulator targeting synaptic and extrasynaptic GABA receptors

Sleep disorders

A phase I/II study of healthy adult volunteers showed it significantly improved sleep efficiency (SE), the primary endpoint of the trial, to a median of 85% (30 mg; p<0.0001) and 88% (45 mg; p<0.0001), respectively, compared with a median SE of 73% for placebo; it also demonstrated statistically significant improvements in total sleep time as well as sleep maintenance; it was generally well-tolerated

2/1/18

Xenon Pharmaceuticals Inc. (Burnaby, British Columbia)

XEN-901

Oral, small-molecule Nav1.6 sodium channel inhibitor

Epilepsy

Started a phase I trial

2/21/18

Ocular

Regenxbio Inc. (Rockville, Md.)

RGX-314

Includes the NAV AAV8 vector encoding an antibody fragment which inhibits VEGF

Wet age-related macular degeneration

Completed dosing of the third cohort of six patients in a phase I trial

2/12/18

Santen Inc. (Emeryville, Calif.)

DE-122

Carotuximab

Refractory wet age-related macular degeneration

Phase I/II data showed it was well tolerated with no serious adverse events reported; there were signs of its bioactivity as measured by mean change in central retinal subfield thickness based on the spectral domain optical coherence tomography

2/13/18

Other/Miscellaneous

Adverum Biotechnologies Inc (Menlo Park, Calif.)

ADVM-043

Gene therapy

Alpha-1 antitrypsin deficiency

Completed dosing and evaluation of patients (n=2) in the first cohort of the ADVANCE phase I/II trial

2/27/18

Respiratory

Pulmatrix Inc. (Lexington, Mass.)

Pulmazole

Itraconazole

Allergic bronchopulmonary aspergillosis in patients with asthma

Treated the first subject in a phase I/Ib trial

2/13/18

Notes

The date indicated refers to the BioWorld issue in which the news item can be found.

For more information about individual companies and/or products, see Cortellis.